Evidence map›Paper›PMID 37765056›Full record

ArticlePharmaceuticals (Basel, Switzerland)2023

s-Triazine Derivatives Functionalized with Alkylating 2-Chloroethylamine Fragments as Promising Antimicrobial Agents: Inhibition of Bacterial DNA Gyrases, Molecular Docking Studies, and Antibacterial and Antifungal Activity.

Dawid Maliszewski, Rasime Demirel, Agnieszka Wróbel, Maciej Baradyn, Artur Ratkiewicz, Danuta Drozdowska

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Deciphering the biocontrol strategies ofCurrent research in microbial sciences · 2025
    Article
  6. New Steroidal Selenides as Proapoptotic Factors.Molecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Dawid MaliszewskiDepartment of Organic Chemistry, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-8407-081X
Rasime DemirelDepartment of Biology, Eskisehir Technical University, Eskişehir 26555, Turkey.
Agnieszka WróbelDepartment of Organic Chemistry, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0003-4493-1547
Maciej BaradynFaculty of Chemistry, University of Bialystok, 15-245 Bialystok, Poland.
Artur RatkiewiczFaculty of Chemistry, University of Bialystok, 15-245 Bialystok, Poland.ORCID 0000-0003-1657-1871
Danuta DrozdowskaDepartment of Organic Chemistry, Medical University of Bialystok, 15-089 Bialystok, Poland.ORCID 0000-0002-3479-0480
Medical University of Białystok · PLUniversity of Białystok · PLEskisehir Technical University · TR

Funding

European Union PO WER 2014-2020Medical University of Bialystok, Poland SUB/2/DN/22/002/2204
6 · The paper itself

Abstract

The spectrum of biological properties of s-triazine derivatives is broad and includes anti-microbial, anti-cancer, and anti-neurodegenerative activities, among others. The s-triazine molecule, due to the possibility of substituting three substituents, offers many opportunities to obtain hybrid compounds with a wide variety of activities. A group of 1,3,5 triazine derivatives containing a dipeptide, 2-ethylpiperazine, and a methoxy group as substituents was screened for their antimicrobial activity. An in vitro study was conducted on pathogenic bacteria (

Indexed as

alkylating agentsantibacterial agentantifungal agentDNA gyrasetriazine scaffold

Identifiers

PMID37765056
PMCPMC10650753
OpenAlexW4386423479

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.